APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Drugs Market Outlook and Growth Opportunities 2026

Report ID 174029950422 December 2025211 pages

Choose your research edition.

Industry ResearchPulmonary Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Pulmonary Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Drugs market include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, GlaxoSmithKline Plc., Glenmark Pharmaceuticals Ltd., AbbVie Inc., AstraZeneca Plc., Zambon Company S.p.A and Wellona Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pulmonary Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pulmonary Drugs market.

Pulmonary Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

GlaxoSmithKline Plc.

Glenmark Pharmaceuticals Ltd.

AbbVie Inc.

AstraZeneca Plc.

Zambon Company S.p.A

Wellona Pharma

Vertex Pharmaceuticals Inc.

Sumitomo Pharma Co. Ltd.

Merck Sharp & Dohme Limited

Medisol Lifescience Pvt. Ltd.

Meda Pharmaceuticals

Mallinckrodt Pharmaceuticals Plc.

Lupin Ltd.

Grifols, S.A.

F. Hoffmann La Roche Ltd.

Circassia Pharmaceuticals Plc.

Cipla Ltd.

Cheisi Farmaceutici S.p.A

Celon Pharma SA

Boehringer Ingelheim

Aurobindo Pharma Ltd.

Alaxia SAS

Aerogen Pharma Ltd.

Abbott Laboratories

Pulmonary Drugs Segment by Type

Antihistamines

Inhaled Corticosteroids

Vasodilators

Long Acting Beta-2 Agonists

Others

Pulmonary Drugs Segment by Application

Asthma & COPD

Cystic Fibrosis

Pulmonary Arterial Hypertension

Allergic Rhinitis

Others

Pulmonary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pulmonary Drugs key companies, revenue, market share, and recent developments.

3. To split the Pulmonary Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pulmonary Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Drugs industry.

Chapter 3: Detailed analysis of Pulmonary Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pulmonary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pulmonary Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Drugs Industry Trends Table 2. Pulmonary Drugs Industry Drivers Table 3. Pulmonary Drugs Industry Opportunities and Challenges Table 4. Pulmonary Drugs Industry Restraints Table 5. Global Pulmonary Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Drugs Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pulmonary Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Pulmonary Drugs Company, Product Type & Application Table 10. Global Pulmonary Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pulmonary Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antihistamines Table 15. Significant Companies of Inhaled Corticosteroids Table 16. Significant Companies of Vasodilators Table 17. Significant Companies of Long Acting Beta-2 Agonists Table 18. Significant Companies of Others Table 19. Global Pulmonary Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Pulmonary Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Pulmonary Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Pulmonary Drugs Sales Value Share by Type (2021-2026) Table 23. Global Pulmonary Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Asthma & COPD Table 25. Significant Companies of Cystic Fibrosis Table 26. Significant Companies of Pulmonary Arterial Hypertension Table 27. Significant Companies of Allergic Rhinitis Table 28. Significant Companies of Others Table 29. Global Pulmonary Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pulmonary Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Pulmonary Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Pulmonary Drugs Sales Value Share by Application (2021-2026) Table 33. Global Pulmonary Drugs Sales Value Share by Application (2027-2032) Table 34. Global Pulmonary Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Pulmonary Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Pulmonary Drugs Sales Value Share by Region (2021-2026) Table 37. Global Pulmonary Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Pulmonary Drugs Sales Value Share by Region (2027-2032) Table 39. Global Pulmonary Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pulmonary Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Pulmonary Drugs Sales Value Market Share by Country (2021-2026) Table 42. Global Pulmonary Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Pulmonary Drugs Sales Value Market Share by Country (2027-2032) Table 44. Teva Pharmaceutical Industries Ltd. Company Information Table 45. Teva Pharmaceutical Industries Ltd. Business Overview Table 46. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio Table 48. Teva Pharmaceutical Industries Ltd. Recent Development Table 49. Sanofi SA Company Information Table 50. Sanofi SA Business Overview Table 51. Sanofi SA Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi SA Pulmonary Drugs Product Portfolio Table 53. Sanofi SA Recent Development Table 54. Novartis AG Company Information Table 55. Novartis AG Business Overview Table 56. Novartis AG Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis AG Pulmonary Drugs Product Portfolio Table 58. Novartis AG Recent Development Table 59. GlaxoSmithKline Plc. Company Information Table 60. GlaxoSmithKline Plc. Business Overview Table 61. GlaxoSmithKline Plc. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio Table 63. GlaxoSmithKline Plc. Recent Development Table 64. Glenmark Pharmaceuticals Ltd. Company Information Table 65. Glenmark Pharmaceuticals Ltd. Business Overview Table 66. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio Table 68. Glenmark Pharmaceuticals Ltd. Recent Development Table 69. AbbVie Inc. Company Information Table 70. AbbVie Inc. Business Overview Table 71. AbbVie Inc. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AbbVie Inc. Pulmonary Drugs Product Portfolio Table 73. AbbVie Inc. Recent Development Table 74. AstraZeneca Plc. Company Information Table 75. AstraZeneca Plc. Business Overview Table 76. AstraZeneca Plc. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. AstraZeneca Plc. Pulmonary Drugs Product Portfolio Table 78. AstraZeneca Plc. Recent Development Table 79. Zambon Company S.p.A Company Information Table 80. Zambon Company S.p.A Business Overview Table 81. Zambon Company S.p.A Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Zambon Company S.p.A Pulmonary Drugs Product Portfolio Table 83. Zambon Company S.p.A Recent Development Table 84. Wellona Pharma Company Information Table 85. Wellona Pharma Business Overview Table 86. Wellona Pharma Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Wellona Pharma Pulmonary Drugs Product Portfolio Table 88. Wellona Pharma Recent Development Table 89. Vertex Pharmaceuticals Inc. Company Information Table 90. Vertex Pharmaceuticals Inc. Business Overview Table 91. Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio Table 93. Vertex Pharmaceuticals Inc. Recent Development Table 94. Sumitomo Pharma Co. Ltd. Company Information Table 95. Sumitomo Pharma Co. Ltd. Business Overview Table 96. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio Table 98. Sumitomo Pharma Co. Ltd. Recent Development Table 99. Merck Sharp & Dohme Limited Company Information Table 100. Merck Sharp & Dohme Limited Business Overview Table 101. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio Table 103. Merck Sharp & Dohme Limited Recent Development Table 104. Medisol Lifescience Pvt. Ltd. Company Information Table 105. Medisol Lifescience Pvt. Ltd. Business Overview Table 106. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio Table 108. Medisol Lifescience Pvt. Ltd. Recent Development Table 109. Meda Pharmaceuticals Company Information Table 110. Meda Pharmaceuticals Business Overview Table 111. Meda Pharmaceuticals Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Meda Pharmaceuticals Pulmonary Drugs Product Portfolio Table 113. Meda Pharmaceuticals Recent Development Table 114. Mallinckrodt Pharmaceuticals Plc. Company Information Table 115. Mallinckrodt Pharmaceuticals Plc. Business Overview Table 116. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 118. Mallinckrodt Pharmaceuticals Plc. Recent Development Table 119. Lupin Ltd. Company Information Table 120. Lupin Ltd. Business Overview Table 121. Lupin Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Lupin Ltd. Pulmonary Drugs Product Portfolio Table 123. Lupin Ltd. Recent Development Table 124. Grifols, S.A. Company Information Table 125. Grifols, S.A. Business Overview Table 126. Grifols, S.A. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Grifols, S.A. Pulmonary Drugs Product Portfolio Table 128. Grifols, S.A. Recent Development Table 129. F. Hoffmann La Roche Ltd. Company Information Table 130. F. Hoffmann La Roche Ltd. Business Overview Table 131. F. Hoffmann La Roche Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio Table 133. F. Hoffmann La Roche Ltd. Recent Development Table 134. Circassia Pharmaceuticals Plc. Company Information Table 135. Circassia Pharmaceuticals Plc. Business Overview Table 136. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 138. Circassia Pharmaceuticals Plc. Recent Development Table 139. Cipla Ltd. Company Information Table 140. Cipla Ltd. Business Overview Table 141. Cipla Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Cipla Ltd. Pulmonary Drugs Product Portfolio Table 143. Cipla Ltd. Recent Development Table 144. Cheisi Farmaceutici S.p.A Company Information Table 145. Cheisi Farmaceutici S.p.A Business Overview Table 146. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio Table 148. Cheisi Farmaceutici S.p.A Recent Development Table 149. Celon Pharma SA Company Information Table 150. Celon Pharma SA Business Overview Table 151. Celon Pharma SA Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Celon Pharma SA Pulmonary Drugs Product Portfolio Table 153. Celon Pharma SA Recent Development Table 154. Boehringer Ingelheim Company Information Table 155. Boehringer Ingelheim Business Overview Table 156. Boehringer Ingelheim Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Boehringer Ingelheim Pulmonary Drugs Product Portfolio Table 158. Boehringer Ingelheim Recent Development Table 159. Aurobindo Pharma Ltd. Company Information Table 160. Aurobindo Pharma Ltd. Business Overview Table 161. Aurobindo Pharma Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 162. Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio Table 163. Aurobindo Pharma Ltd. Recent Development Table 164. Alaxia SAS Company Information Table 165. Alaxia SAS Business Overview Table 166. Alaxia SAS Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 167. Alaxia SAS Pulmonary Drugs Product Portfolio Table 168. Alaxia SAS Recent Development Table 169. Aerogen Pharma Ltd. Company Information Table 170. Aerogen Pharma Ltd. Business Overview Table 171. Aerogen Pharma Ltd. Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 172. Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio Table 173. Aerogen Pharma Ltd. Recent Development Table 174. Abbott Laboratories Company Information Table 175. Abbott Laboratories Business Overview Table 176. Abbott Laboratories Pulmonary Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 177. Abbott Laboratories Pulmonary Drugs Product Portfolio Table 178. Abbott Laboratories Recent Development Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. Pulmonary Drugs Product Image Figure 2. Global Pulmonary Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antihistamines Image Figure 8. Inhaled Corticosteroids Image Figure 9. Vasodilators Image Figure 10. Long Acting Beta-2 Agonists Image Figure 11. Others Image Figure 12. Global Pulmonary Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Pulmonary Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Pulmonary Drugs Sales Value Share by Type (2021-2032) Figure 15. Asthma & COPD Image Figure 16. Cystic Fibrosis Image Figure 17. Pulmonary Arterial Hypertension Image Figure 18. Allergic Rhinitis Image Figure 19. Others Image Figure 20. Global Pulmonary Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Pulmonary Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Pulmonary Drugs Sales Value Share by Application (2021-2032) Figure 23. Global Pulmonary Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Pulmonary Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Pulmonary Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. North America Pulmonary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Pulmonary Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Pulmonary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Pulmonary Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Pulmonary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Pulmonary Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. South America Pulmonary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Pulmonary Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Pulmonary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Pulmonary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Antihistamines
  • Inhaled Corticosteroids
  • Vasodilators
  • Long Acting Beta-2 Agonists
  • Others
Applications
  • Asthma & COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension
  • Allergic Rhinitis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Glenmark Pharmaceuticals Ltd.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Zambon Company S.p.A
  • Wellona Pharma
  • Vertex Pharmaceuticals Inc.
  • Sumitomo Pharma Co. Ltd.
  • Merck Sharp & Dohme Limited
  • Medisol Lifescience Pvt. Ltd.
  • Meda Pharmaceuticals
  • Mallinckrodt Pharmaceuticals Plc.
  • Lupin Ltd.
  • Grifols, S.A.
  • F. Hoffmann La Roche Ltd.
  • Circassia Pharmaceuticals Plc.
  • Cipla Ltd.
  • Cheisi Farmaceutici S.p.A
  • Celon Pharma SA
  • Boehringer Ingelheim
  • Aurobindo Pharma Ltd.
  • Alaxia SAS
  • Aerogen Pharma Ltd.
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pulmonary Drugs Market Dynamics
  1. 2.1 Pulmonary Drugs Industry Trends
  2. 2.2 Pulmonary Drugs Industry Drivers
  3. 2.3 Pulmonary Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Drugs Industry Restraints
3 Pulmonary Drugs Market by Company
  1. 3.1 Global Pulmonary Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Drugs Company Ranking (2024-2026)
  4. 3.4 Global Pulmonary Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Pulmonary Drugs Company Product Type and Application
  6. 3.6 Global Pulmonary Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pulmonary Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pulmonary Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pulmonary Drugs Market by Type
  1. 4.1 Pulmonary Drugs Type Introduction
  2. 4.1.1 Antihistamines
  3. 4.1.2 Inhaled Corticosteroids
  4. 4.1.3 Vasodilators
  5. 4.1.4 Long Acting Beta-2 Agonists
  6. 4.1.5 Others
  7. 4.2 Global Pulmonary Drugs Sales Value by Type
  8. 4.2.1 Global Pulmonary Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pulmonary Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Pulmonary Drugs Sales Value Share by Type (2021-2032)
5 Pulmonary Drugs Market by Application
  1. 5.1 Pulmonary Drugs Application Introduction
  2. 5.1.1 Asthma & COPD
  3. 5.1.2 Cystic Fibrosis
  4. 5.1.3 Pulmonary Arterial Hypertension
  5. 5.1.4 Allergic Rhinitis
  6. 5.1.5 Others
  7. 5.2 Global Pulmonary Drugs Sales Value by Application
  8. 5.2.1 Global Pulmonary Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Pulmonary Drugs Sales Value by Application (2021-2032)
  10. 5.2.3 Global Pulmonary Drugs Sales Value Share by Application (2021-2032)
6 Pulmonary Drugs Regional Value Analysis
  1. 6.1 Global Pulmonary Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Pulmonary Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pulmonary Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Pulmonary Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pulmonary Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pulmonary Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pulmonary Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Pulmonary Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pulmonary Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pulmonary Drugs Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Drugs Country-level Value Analysis
  1. 7.1 Global Pulmonary Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pulmonary Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pulmonary Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pulmonary Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pulmonary Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pulmonary Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Sanofi SA
  8. 8.2.1 Sanofi SA Company Information
  9. 8.2.2 Sanofi SA Business Overview
  10. 8.2.3 Sanofi SA Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi SA Pulmonary Drugs Product Portfolio
  12. 8.2.5 Sanofi SA Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Pulmonary Drugs Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 GlaxoSmithKline Plc.
  20. 8.4.1 GlaxoSmithKline Plc. Company Information
  21. 8.4.2 GlaxoSmithKline Plc. Business Overview
  22. 8.4.3 GlaxoSmithKline Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc. Recent Developments
  25. 8.5 Glenmark Pharmaceuticals Ltd.
  26. 8.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 8.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 8.5.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio
  30. 8.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 8.6 AbbVie Inc.
  32. 8.6.1 AbbVie Inc. Company Information
  33. 8.6.2 AbbVie Inc. Business Overview
  34. 8.6.3 AbbVie Inc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Inc. Pulmonary Drugs Product Portfolio
  36. 8.6.5 AbbVie Inc. Recent Developments
  37. 8.7 AstraZeneca Plc.
  38. 8.7.1 AstraZeneca Plc. Company Information
  39. 8.7.2 AstraZeneca Plc. Business Overview
  40. 8.7.3 AstraZeneca Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Plc. Pulmonary Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Plc. Recent Developments
  43. 8.8 Zambon Company S.p.A
  44. 8.8.1 Zambon Company S.p.A Company Information
  45. 8.8.2 Zambon Company S.p.A Business Overview
  46. 8.8.3 Zambon Company S.p.A Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zambon Company S.p.A Pulmonary Drugs Product Portfolio
  48. 8.8.5 Zambon Company S.p.A Recent Developments
  49. 8.9 Wellona Pharma
  50. 8.9.1 Wellona Pharma Company Information
  51. 8.9.2 Wellona Pharma Business Overview
  52. 8.9.3 Wellona Pharma Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Wellona Pharma Pulmonary Drugs Product Portfolio
  54. 8.9.5 Wellona Pharma Recent Developments
  55. 8.10 Vertex Pharmaceuticals Inc.
  56. 8.10.1 Vertex Pharmaceuticals Inc. Company Information
  57. 8.10.2 Vertex Pharmaceuticals Inc. Business Overview
  58. 8.10.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio
  60. 8.10.5 Vertex Pharmaceuticals Inc. Recent Developments
  61. 8.11 Sumitomo Pharma Co. Ltd.
  62. 8.11.1 Sumitomo Pharma Co. Ltd. Company Information
  63. 8.11.2 Sumitomo Pharma Co. Ltd. Business Overview
  64. 8.11.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio
  66. 8.11.5 Sumitomo Pharma Co. Ltd. Recent Developments
  67. 8.12 Merck Sharp & Dohme Limited
  68. 8.12.1 Merck Sharp & Dohme Limited Company Information
  69. 8.12.2 Merck Sharp & Dohme Limited Business Overview
  70. 8.12.3 Merck Sharp & Dohme Limited Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio
  72. 8.12.5 Merck Sharp & Dohme Limited Recent Developments
  73. 8.13 Medisol Lifescience Pvt. Ltd.
  74. 8.13.1 Medisol Lifescience Pvt. Ltd. Company Information
  75. 8.13.2 Medisol Lifescience Pvt. Ltd. Business Overview
  76. 8.13.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio
  78. 8.13.5 Medisol Lifescience Pvt. Ltd. Recent Developments
  79. 8.14 Meda Pharmaceuticals
  80. 8.14.1 Meda Pharmaceuticals Company Information
  81. 8.14.2 Meda Pharmaceuticals Business Overview
  82. 8.14.3 Meda Pharmaceuticals Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Meda Pharmaceuticals Pulmonary Drugs Product Portfolio
  84. 8.14.5 Meda Pharmaceuticals Recent Developments
  85. 8.15 Mallinckrodt Pharmaceuticals Plc.
  86. 8.15.1 Mallinckrodt Pharmaceuticals Plc. Company Information
  87. 8.15.2 Mallinckrodt Pharmaceuticals Plc. Business Overview
  88. 8.15.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  90. 8.15.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
  91. 8.16 Lupin Ltd.
  92. 8.16.1 Lupin Ltd. Company Information
  93. 8.16.2 Lupin Ltd. Business Overview
  94. 8.16.3 Lupin Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Lupin Ltd. Pulmonary Drugs Product Portfolio
  96. 8.16.5 Lupin Ltd. Recent Developments
  97. 8.17 Grifols, S.A.
  98. 8.17.1 Grifols, S.A. Company Information
  99. 8.17.2 Grifols, S.A. Business Overview
  100. 8.17.3 Grifols, S.A. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Grifols, S.A. Pulmonary Drugs Product Portfolio
  102. 8.17.5 Grifols, S.A. Recent Developments
  103. 8.18 F. Hoffmann La Roche Ltd.
  104. 8.18.1 F. Hoffmann La Roche Ltd. Company Information
  105. 8.18.2 F. Hoffmann La Roche Ltd. Business Overview
  106. 8.18.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio
  108. 8.18.5 F. Hoffmann La Roche Ltd. Recent Developments
  109. 8.19 Circassia Pharmaceuticals Plc.
  110. 8.19.1 Circassia Pharmaceuticals Plc. Company Information
  111. 8.19.2 Circassia Pharmaceuticals Plc. Business Overview
  112. 8.19.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  114. 8.19.5 Circassia Pharmaceuticals Plc. Recent Developments
  115. 8.20 Cipla Ltd.
  116. 8.20.1 Cipla Ltd. Company Information
  117. 8.20.2 Cipla Ltd. Business Overview
  118. 8.20.3 Cipla Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cipla Ltd. Pulmonary Drugs Product Portfolio
  120. 8.20.5 Cipla Ltd. Recent Developments
  121. 8.21 Cheisi Farmaceutici S.p.A
  122. 8.21.1 Cheisi Farmaceutici S.p.A Company Information
  123. 8.21.2 Cheisi Farmaceutici S.p.A Business Overview
  124. 8.21.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio
  126. 8.21.5 Cheisi Farmaceutici S.p.A Recent Developments
  127. 8.22 Celon Pharma SA
  128. 8.22.1 Celon Pharma SA Company Information
  129. 8.22.2 Celon Pharma SA Business Overview
  130. 8.22.3 Celon Pharma SA Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Celon Pharma SA Pulmonary Drugs Product Portfolio
  132. 8.22.5 Celon Pharma SA Recent Developments
  133. 8.23 Boehringer Ingelheim
  134. 8.23.1 Boehringer Ingelheim Company Information
  135. 8.23.2 Boehringer Ingelheim Business Overview
  136. 8.23.3 Boehringer Ingelheim Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Boehringer Ingelheim Pulmonary Drugs Product Portfolio
  138. 8.23.5 Boehringer Ingelheim Recent Developments
  139. 8.24 Aurobindo Pharma Ltd.
  140. 8.24.1 Aurobindo Pharma Ltd. Company Information
  141. 8.24.2 Aurobindo Pharma Ltd. Business Overview
  142. 8.24.3 Aurobindo Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio
  144. 8.24.5 Aurobindo Pharma Ltd. Recent Developments
  145. 8.25 Alaxia SAS
  146. 8.25.1 Alaxia SAS Company Information
  147. 8.25.2 Alaxia SAS Business Overview
  148. 8.25.3 Alaxia SAS Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Alaxia SAS Pulmonary Drugs Product Portfolio
  150. 8.25.5 Alaxia SAS Recent Developments
  151. 8.26 Aerogen Pharma Ltd.
  152. 8.26.1 Aerogen Pharma Ltd. Company Information
  153. 8.26.2 Aerogen Pharma Ltd. Business Overview
  154. 8.26.3 Aerogen Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio
  156. 8.26.5 Aerogen Pharma Ltd. Recent Developments
  157. 8.27 Abbott Laboratories
  158. 8.27.1 Abbott Laboratories Company Information
  159. 8.27.2 Abbott Laboratories Business Overview
  160. 8.27.3 Abbott Laboratories Pulmonary Drugs Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Abbott Laboratories Pulmonary Drugs Product Portfolio
  162. 8.27.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst